日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Resistance mechanisms to immune checkpoint inhibitors: updated insights

免疫检查点抑制剂耐药机制:最新见解

Alsaafeen, Besan H; Ali, Bassam R; Elkord, Eyad

TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies

TIGIT在癌症中的作用:从作用机制到有前景的免疫治疗策略

Cui, Haozhe; Hamad, Mawieh; Elkord, Eyad

Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

克服免疫检查点抑制剂耐药性的联合治疗策略

Alsaafeen, Besan H; Ali, Bassam R; Elkord, Eyad

Editorial: Community series in novel biomarkers in tumor immunity and immunotherapy, volume II

社论:肿瘤免疫和免疫疗法新型生物标志物系列丛书,第二卷

Elkord, Eyad; Matsutani, Takaji

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy

结直肠癌微环境:癌症治疗靶点识别的临床前进展

Meyiah, Abdo; Khan, Faez Iqbal; Alfaki, Dia Aldeen; Murshed, Khaled; Raza, Afsheen; Elkord, Eyad

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

淋巴细胞活化基因3在癌症免疫治疗中的应用:功能、预后生物标志物和治疗潜力

Ren, Ke; Hamdy, Hayam; Meyiah, Abdo; Elkord, Eyad

Editorial: Novel biomarkers in tumor immunity and immunotherapy

社论:肿瘤免疫和免疫治疗中的新型生物标志物

Matsutani, Takaji; Akbay, Esra; Elkord, Eyad

Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation.

乳香树脂中 3-O-乙酰基-11-酮基-β-乳香酸的 1H-1,2,3-三唑衍生物对 T 细胞增殖和活化的影响

Meyiah Abdo, Avula Satya Kumar, Al-Harrasi Ahmed, Elkord Eyad

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?

将癌症免疫疗法转向新兴的免疫检查点 TIGIT:这能否突破传统方法的局限性?

Cui, Haozhe; Elkord, Eyad

Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

癌症免疫疗法中的非编码RNA:预测性生物标志物和靶点

Alahdal, Murad; Elkord, Eyad